Growth In The Pharmaceutical Continuous Manufacturing Market Is Being Driven By Rising Incidence Of Dermatitis Driving Growth Due To Increased Need For Effective Dermatological Treatments
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Pharmaceutical Continuous Manufacturing Market Projected To Reach By 2030?
The pharmaceutical continuous manufacturing market size has experienced significant expansion in recent years. It is anticipated to grow from $2.69 billion in 2025 to $2.97 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. The historical rise in this market can be linked to factors like increasing drug demand volumes, the necessity for improved production efficiency, notable variability in batch manufacturing, mounting cost pressures on pharmaceutical companies, and early regulatory pilot approvals.
The pharmaceutical continuous manufacturing market size is anticipated to experience significant expansion over the next few years, projected to reach $4.58 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.4%. This growth in the outlook period is primarily driven by factors such as the increasing adoption of PCM by major pharmaceutical firms, a rise in investment toward smart factories, the escalating demand for expedited scale-up and commercialization, a heightened focus on ensuring supply chain resilience, and continuous advancements in continuous processing equipment. Noteworthy trends during the forecast period include a strategic shift from traditional batch production to end-to-end continuous processes, the wider implementation of modular and adaptable manufacturing lines, an intensifying emphasis on real-time quality assurance and precise control, the expansion of continuous manufacturing for Active Pharmaceutical Ingredient (API) production, and growing support from regulatory bodies for continuous manufacturing methodologies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12123&type=smp
Which Strong Drivers Are Impacting The Pharmaceutical Continuous Manufacturing Market Growth?
The anticipated expansion of the pharmaceutical continuous manufacturing market is linked to the rising adoption of industrial automation. Industrial automation involves employing control systems, like computers and robots, to manage various industrial processes and machinery, either replacing or assisting human involvement. Within pharmaceutical continuous manufacturing, industrial automation aids in monitoring and providing real-time feedback control for CM processes, thereby reducing human errors and guaranteeing uniform product quality. An example illustrating this trend is provided by the World Robotics report from September 2023, issued by the International Federation of Robotics, a professional non-profit organization located in Germany, which indicated that 553,052 industrial robots were installed globally in factories, reflecting a 5% year-on-year growth rate in 2022. Consequently, the growing prevalence of industrial automation is a key factor propelling the expansion of the pharmaceutical continuous manufacturing market.
How Is The Pharmaceutical Continuous Manufacturing Market Organized By Segment Classification?
The pharmaceutical continuous manufacturing market covered in this report is segmented –
1) By Product: Integrated Continuous System, Control And Software, Semi-Continuous System
2) By Therapeutics Type: Large Molecule, Small Molecule
3) By Formulation: Solid Formation, Liquid And Semi-Solid Formation
4) By Application: Final Drug Product Manufacturing, Active Pharmaceutical Ingredient (API) Manufacturing
5) By End-Users: Pharmaceutical Companies, Contract Manufacturing Organization, Other End-Users
Subsegments:
1) By Integrated Continuous System: Continuous Mixer Systems, Continuous Granulation Systems, Continuous Tablet Press Systems, Continuous Coating Systems
2) By Control and Software: Process Analytical Technology (PAT) Tools, Manufacturing Execution Systems (MES), Control Software for Automation, Data Management and Visualization Software
3) By Semi-Continuous System: Batch-to-Continuous Transition Systems, Hybrid Systems, Semi-Continuous Granulation and Drying Systems
Which Trends Are Contributing To Changes In The Pharmaceutical Continuous Manufacturing Market?
Major companies engaged in the pharmaceutical continuous manufacturing market are prioritizing the creation of advanced equipment, specifically continuous manufacturing lines, to secure a competitive edge within the industry. A Continuous Manufacturing (CM) line is defined as a specialized production framework where raw materials are seamlessly processed into finished products without any interruptions or pauses. An example of this occurred in January 2023, when WuXi STA, a China-based contract research, development, and manufacturing organization (CRDMO), inaugurated a Continuous Manufacturing (CM) line for oral solids in Wuxi City, China. This CM line, which complies with global cGMP regulations, introduces advancements in oral drug development by integrating continuous direct compression equipment for dispensing, blending, lubrication, tablet compression, and coating. Furthermore, Process Analytical Technology (PAT) is integrated to oversee blending uniformity in real-time, thereby assuring high product quality.
Who Are The Industry Participants Involved In The Pharmaceutical Continuous Manufacturing Market?
Major companies operating in the pharmaceutical continuous manufacturing market are Pfizer Inc., Robert Bosch GmbH, Siemens AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., Eli Lilly and Company, Corning Inc., Vertex Pharmaceuticals, Lonza Group Ltd., GEA Group AG, Catalent Inc., Mettler Toledo, Patheon, Cytiva, Samsung Biologics Co.Ltd., WuXi Biologics, Syntegon Technology GmbH, Coperion GmbH, Hosokawa Micron Group, FUJIFILM Diosynth Biotechnologies, Leistritz AG, Glatt GmbH, Freund-Vector Corp., SK biotek Co. Ltd., Gericke AG, GEBRÜDER LÖDIGE MASCHINENBAU GmbH, Munson Machinery Company Inc., L.B. Bohle Maschinen und Verfahren GmbH, KORSCH AG, Chemtrix BV
Get The Full Pharmaceutical Continuous Manufacturing Market Report:
Which Region Has The Greatest Market Share In The Pharmaceutical Continuous Manufacturing Market?
Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical continuous manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Pharmaceutical Continuous Manufacturing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Pharmaceutical Continuous Manufacturing Market 2026, By The Business Research Company
Pharmaceutical Continuous Manufacturing Market Report 2026
Fill Finish Pharmaceutical Contract Manufacturing Market Report 2026
Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
